Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: EVENT HORIZON III who wrote (375)	1/12/2003 9:33:33 PM
From: Mike	Respond to of 423

Jeff, First what happened in mid Novemeber. The Replace 2 trial was presented at the American Heart Association meeting in Chicago. The company hit a "homerun" in hitting all primary and secondary endpoints of the Replace 2 trial. This was one of the largest cath lab trials in years. The results can be accessed from the site below and going to investor relations. themedicinescompany.com The sales for MDCO for '02 are going to be $38M and projections for '03 are in the $70M-$90M range. This one also has some news coming out in JAMA (major physician publication) article to be published in the next two weeks on Replace 2. If you have time and can take a look let me know your thoughts. Would love to have a financial modeling discussion on this one to determine "valuation". Thanks again for the response, Mike